Hepatitis/MASH

The authors note that this may cause disruptions in the metabolic stability of lipid processing and storage, impacting the liver and accelerating damaging adaptative responses.

The study shows benefits when Hecolin (HEV 239; Xiamen Innovax Biotech Co Ltd) is administered in 2 doses, rather than the typical 3-dose regimen.

Despite the reductions in hepatitis B surface antigen (HBsAg), grade 3 and 4 adverse events were not uncommon.

Severe alcohol-associated hepatitis has limited effective pharmacological therapies, emphasizing the need for treatment options.

New medications like glucagon-like peptide-1 agonists and resmetirom show promise in reversing fatty liver disease and preventing progression.

The treatments are currently undergoing evaluation in the SOLSTICE trial (NCT05461170).

Survodutide is a glucagon/glucagon-like peptide-1 (GLP-1) receptor dual agonist that activates the glucagon and GLP-1 receptors to better control metabolic function.

Positive trial results laid the groundwork for the designation.

A lack of widespread hepatitis B screenings compound with the issue of inaccurate test results, which can complicate treatment with intravenous immunoglobulin.

Study finds traces of “epigenetic scars” on the immune cells of patients who recovered from chronic hepatitis C infection.

Treatment often involves a complex daily routine of reconstitution and subcutaneous injection, along with strict storage requirements.

In the 2 mg bulevirtide (Gilead Sciences) group, 44% of individuals achieved HDV RNA that was undetectable compared with 70% in the 10 mg group.

Investigators found improvements over the placebo in metabolic dysfunction-associated steatohepatitis without worsening fibrosis across 3 dosing groups.

The test can be performed in settings that operate under the Clinical Laboratory Improvement Amendments waiver, including community pharmacies.

Lindsey P. Sheehan, PharmD, MPA, MBA, discusses ongoing challenges of diagnosing and treating hepatitis C, emphasizing its increased incidence among younger populations and ongoing low rates of diagnosis.

Study investigators hired undercover shoppers, and the results revealed more education is needed on the Syringe Service Program, which provides legal, clean over-the-counter (OTC) needles to whomever seeks them out.

The primary outcome was a 90-day incidence of mortality or liver transplant for individuals who received larsucosterol, compared to the placebo group.

Hepatitis Awareness Month is designed to raise awareness of viral hepatitis and promote testing and vaccination while decreasing the stigma against the virus.

Patients who were formerly incarcerated commonly experience substance use disorder, tuberculosis, hepatitis C, and sexually transmitted diseases

The new indication includes pediatric patients aged 6 years and older who weigh at least 25 kg and have compensated liver disease.

After 48 weeks of treatment with survodutide, patients demonstrated histological improvement, a reduction in liver fat content, and did not experience worsening fibrosis.

In this model, community pharmacists deliver all aspects of treating HCV infection in individuals who inject drugs.

Bepirovirsen is a triple action investigational antisense oligonucleotide and is being evaluated in the B-Well phase 3 clinical trial program for the treatment of chronic hepatitis B.

The results suggest that telemedicine could be used to help improve access for other populations that might be stigmatized, beyond hepatitis C virus and opioid use disorder.

The study investigators said that restricting access to direct-acting antiviral therapy due to alcohol consumption could create unnecessary barriers for those with hepatitis C virus.